Genor Biopharma Has Announced Completion of the Phase I Single-dose Clinical Trial of GB221 in Patients with HER2+ Breast Cancer
calendar
19 Sep, 2019
SHANGHAI, CHINA--Genor Biopharma has announced the completion of the Phase I clinical trial of GB221 in HER2+ breast cancer patients. This randomized, multicenter, single-dose trial evaluated tolerance, safety, pharmacokinetic characteristics and immunogenicity of GB221. The results showed that GB221 was safe and had similar pharmacokinetic and immunogenicity characteristics to Herceptin.
1273
Genor Biopharma Has Announced Completion of the Phase I Single-dose Clinical Trial of GB221 in Patients with HER2+ Breast Cancer
calendar
19 Sep, 2019
SHANGHAI, CHINA--Genor Biopharma has announced the completion of the Phase I clinical trial of GB221 in HER2+ breast cancer patients. This randomized, multicenter, single-dose trial evaluated tolerance, safety, pharmacokinetic characteristics and immunogenicity of GB221. The results showed that GB221 was safe and had similar pharmacokinetic and immunogenicity characteristics to Herceptin.
1255